Startup Founder Interview: How Loomee Is Using Agentic AI to Transform Clinical Mental Health Care

The startup Loomee focuses on AI-powered clinical mental health SaaS solutions. The world health organization reports that one in four people will experience a mental health issue in their lifetime, yet there is a severe shortage of clinical psychologists, with a deficit of 150,000 specialists in the EU alone. Therapists spend up to 40% of their time on administrative tasks, which hinders patient care.

Loomee's founding team, composed of a CEO with a PhD in Biomedical Engineering, a CSO with a PhD in Psychology, and a CPO with full-stack development expertise, aims to solve this problem by combining clinical psychology, technology, and business.

The team comprises 3 full-time employees, including 2 PhD in Psychology members and a software developer with 25 years of experience. They complement their core leadership with a network of collaborators and expert advisors. If Loomee were not building the startup, the CEO would likely be working at the intersection of corporate innovation and deep tech, helping entrepreneurs bring healthcare technologies to market after 13 years at Airbus and mentoring over 150 startups as Co-Director of the Founder Institute.

Success is measured by professional adoption and the efficiency gains for clinics, currently achieved by reducing administrative workload by 40%. Loomee offers a B2B SaaS platform for psychologists and mental health clinics, paired with a secure mobile app for patients. The platform digitizes the therapeutic process, automates administrative tasks, and provides over 600 evidence-based clinical resources to personalize interventions and improve patient adherence.

The most exciting aspect of Loomee's traction is the institutional and clinical trust gained from securing paying customers early in development and raising funding, including a formal clinical trial project with Hospital Clinico San Carlos in Madrid. Growth next year will focus on transforming clinical validation into international commercial scale, deploying a multi-agent AI ecosystem in 2027, achieving Medical Device certification, and expanding into Latin America.

The startup's first paying customers were clinics that helped validate the platform before a full commercial launch. Revenue expectations for 2026 project over 100,000 euros in sales, with a transition toward recurring SaaS sales and exponential growth by 2027. The biggest threat lies in navigating the strict regulatory landscape, requiring Loomee to be certified as a Class IIa Medical Device under European MDR regulations by 2027.